263 related articles for article (PubMed ID: 16011830)
1. The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees C.
McPate MJ; Duncan RS; Milnes JT; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2005 Aug; 334(2):441-9. PubMed ID: 16011830
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of the short QT N588K mutation at 37 degrees C on hERG K+ channel current during ventricular, Purkinje fibre and atrial action potentials: an action potential clamp study.
McPate MJ; Zhang H; Adeniran I; Cordeiro JM; Witchel HJ; Hancox JC
J Physiol Pharmacol; 2009 Mar; 60(1):23-41. PubMed ID: 19439805
[TBL] [Abstract][Full Text] [Related]
3. Modulation of I(Kr) inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome.
Cordeiro JM; Brugada R; Wu YS; Hong K; Dumaine R
Cardiovasc Res; 2005 Aug; 67(3):498-509. PubMed ID: 16039272
[TBL] [Abstract][Full Text] [Related]
4. Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.
El Harchi A; Melgari D; Zhang YH; Zhang H; Hancox JC
PLoS One; 2012; 7(12):e52451. PubMed ID: 23300672
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.
McPate MJ; Duncan RS; Hancox JC; Witchel HJ
Br J Pharmacol; 2008 Nov; 155(6):957-66. PubMed ID: 18724381
[TBL] [Abstract][Full Text] [Related]
6. Time course and voltage dependence of expressed HERG current compared with native "rapid" delayed rectifier K current during the cardiac ventricular action potential.
Hancox JC; Levi AJ; Witchel HJ
Pflugers Arch; 1998 Nov; 436(6):843-53. PubMed ID: 9799397
[TBL] [Abstract][Full Text] [Related]
7. Mutant MiRP1 subunits modulate HERG K+ channel gating: a mechanism for pro-arrhythmia in long QT syndrome type 6.
Lu Y; Mahaut-Smith MP; Huang CL; Vandenberg JI
J Physiol; 2003 Aug; 551(Pt 1):253-62. PubMed ID: 12923204
[TBL] [Abstract][Full Text] [Related]
8. Biophysical characterization of the short QT mutation hERG-N588K reveals a mixed gain-and loss-of-function.
Grunnet M; Diness TG; Hansen RS; Olesen SP
Cell Physiol Biochem; 2008; 22(5-6):611-24. PubMed ID: 19088443
[TBL] [Abstract][Full Text] [Related]
9. Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome.
McPate MJ; Duncan RS; Witchel HJ; Hancox JC
J Mol Cell Cardiol; 2006 Sep; 41(3):563-6. PubMed ID: 16842817
[TBL] [Abstract][Full Text] [Related]
10. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of the β-adrenoceptor blockers carvedilol and metoprolol on SQT1- and SQT2-mutant channels.
Bodi I; Franke G; Pantulu ND; Wu K; Perez-Feliz S; Bode C; Zehender M; zur Hausen A; Brunner M; Odening KE
J Cardiovasc Electrophysiol; 2013 Oct; 24(10):1163-71. PubMed ID: 23718892
[TBL] [Abstract][Full Text] [Related]
12. A novel mutation in the KCNH2 gene associated with short QT syndrome.
Sun Y; Quan XQ; Fromme S; Cox RH; Zhang P; Zhang L; Guo D; Guo J; Patel C; Kowey PR; Yan GX
J Mol Cell Cardiol; 2011 Mar; 50(3):433-41. PubMed ID: 21130771
[TBL] [Abstract][Full Text] [Related]
13. High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.
Ridley JM; Milnes JT; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2004 Dec; 325(3):883-91. PubMed ID: 15541373
[TBL] [Abstract][Full Text] [Related]
14. hERG1a/1b heteromeric currents exhibit amplified attenuation of inactivation in variant 1 short QT syndrome.
McPate MJ; Zhang H; Cordeiro JM; Dempsey CE; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2009 Aug; 386(1):111-7. PubMed ID: 19501051
[TBL] [Abstract][Full Text] [Related]
15. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels.
Perrin MJ; Kuchel PW; Campbell TJ; Vandenberg JI
Mol Pharmacol; 2008 Nov; 74(5):1443-52. PubMed ID: 18701618
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.
Paul AA; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2001 Feb; 280(5):1243-50. PubMed ID: 11162661
[TBL] [Abstract][Full Text] [Related]
17. Functional interaction between extracellular sodium, potassium and inactivation gating in HERG channels.
Mullins FM; Stepanovic SZ; Gillani NB; George AL; Balser JR
J Physiol; 2004 Aug; 558(Pt 3):729-44. PubMed ID: 15169846
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin.
Duncan RS; McPate MJ; Ridley JM; Gao Z; James AF; Leishman DJ; Leaney JL; Witchel HJ; Hancox JC
Biochem Pharmacol; 2007 Aug; 74(3):425-37. PubMed ID: 17560554
[TBL] [Abstract][Full Text] [Related]
19. A mutation in the pore region of HERG K+ channels expressed in Xenopus oocytes reduces rectification by shifting the voltage dependence of inactivation.
Zou A; Xu QP; Sanguinetti MC
J Physiol; 1998 May; 509 ( Pt 1)(Pt 1):129-37. PubMed ID: 9547387
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline.
Teschemacher AG; Seward EP; Hancox JC; Witchel HJ
Br J Pharmacol; 1999 Sep; 128(2):479-85. PubMed ID: 10510461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
